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Despite being one of the most efficacious drugs used in the treatment of basal cell carcinoma (BCC), 21 
imiquimod has limited cutaneous permeation. The current work presents the development of 22 
polyvinylpyrrolidone-co-vinyl acetate (PVPVA) microneedles loaded with imiquimod for improving 23 
intradermal delivery of imiquimod for the treatment of nodular BCC.  In vitro permeation studies, 24 
using full thickness ex vivo porcine skin were used to evaluate the effectiveness of these imiquimod 25 
loaded polymeric microneedles in comparison to the topical application of commercial AldaraTM 26 
cream. HPLC analysis demonstrated similar intradermal permeation of imiquimod from AldaraTM 27 
cream and imiquimod-loaded microneedles despite the microneedle having a six-fold lower drug 28 
loading than the clinical dose of AldaraTM used for BCC management. In addition, ToF-SIMS analysis of 29 
skin cross sections demonstrated intradermal localisation of imiquimod following microneedle-based 30 
delivery while the AldaraTM treated skin showed the drug localised predominantly within the stratum 31 
corneum. ToF-SIMS analysis also demonstrated intradermal co-localisation of the PVPVA polymer, 32 
used in fabricating the microneedle, with imiquimod within the microneedle channels in a label-free 33 
manner. This study demonstrates that a polymeric microneedle system may be a viable approach to 34 
improving the intradermal delivery of imiquimod for the treatment of nodular BCC with lower drug 35 
loading. 36 
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1. Introduction 44 
Basal cell carcinoma (BCC) is the most prevalent type of skin cancer, with the number of individuals 45 
affected by the disease escalating worldwide. For instance, a large US sex-stratified cohort study by 46 
Wu et al highlighted that the incidence rate of BCC in both men and women have doubled over the 47 
past 20 years (Wu et al., 2013). In addition, similar trends have been reported in Canada, Asia, Australia 48 
and Europe (Cameron et al., 2019). Furthermore, it is anticipated that the incident rate will continue 49 
to escalate due to the rise in an aging population coupled with historical UV exposure  (Diffey and 50 
Langtry, 2005). Given that UV exposure is a risk factor in developing BCC, it therefore quite common 51 
that BCC typically manifests on sun exposed regions of the body such as the face, arms and necks 52 
(Suppa et al., 2015). The two most common BCC subtypes are superficial and nodular (Kuijpers et al., 53 
2002).  Superficial BCC generally manifests as flat red patches on the skin on the skin surface and 54 
proliferates parallel to the epidermis (Colver, 2002; Crowson, 2006). On the other hand, nodular BCC 55 
manifests as a translucent pearly nodule that resides within dermis at approximately 400 µm below 56 
the skin surface (Sabri et al., 2020; Williams et al., 2017). In addition, it has been reported that at least 57 
one-third of nodular BCC coexists with superficial BCC (Goldenberg et al., 2010) 58 
Despite displaying low metastasis rates of 0.0028 %, this form of skin cancer can lead to considerable 59 
local tissue destruction (nose, ears and eyelids) leading to poor cosmetic outcomes and disfigurement 60 
(Mackiewicz-Wysocka et al., 2013; Mehta et al., 2012). The high incidence rate of the disease also 61 
forms a considerable proportion of a dermatologist’s workload (Wu et al., 2015). Therefore, there is a 62 
need to develop a simple and efficacious treatment strategy, which patients could simply administer 63 
by themselves in the management of BCC. Although surgical intervention is effective in treating BCC, 64 
such treatment is both time-consuming and technical (Nijssen et al., 2002). In addition, some patients 65 
may opt for non-surgical alternatives that offer lower overall treatment costs and improved cosmetic 66 
outcomes (Lien and Sondak, 2011; Tinelli et al., 2012). One of the most effective non-surgical 67 
interventions is the topical application of the immunomodulator, imiquimod (Jansen et al., 2017).  68 
Imiquimod is a potent immune response modifier that induces its immunomodulation through Toll-69 
like receptors located on antigen presenting cells. Upon binding to these receptors, imiquimod induces 70 
the release of  pro-inflammatory cytokines which culminate in its antitumoral activity (Lacarrubba et 71 
al., 2008). Imiquimod is marketed as Aldara™ cream (5% w/w) by 3M Pharmaceuticals for the 72 
treatment of anogenital warts, actinic keratosis and superficial BCC. Despite its potency, the drug has 73 
limited dermal permeation thus reducing its therapeutic value to superficial BCC (Ma et al., 2015). 74 
However, in the case of nodular BCC, it has been found that topical therapy with imiquimod typically 75 
has a lower cure rate than surgical intervention (Williams et al., 2017). Such a finding is attributed to 76 
the efficient barrier function of the stratum corneum which limits the permeation of imiquimod into 77 
the skin (Al-Mayahy et al., 2019). In addition, the location of nodular BCC that resides deep within the 78 
aqueous dermis presents another barrier for imiquimod delivery. This is because imiquimod is poorly 79 
water soluble and thereby has limited permeation within the dermis (Sauder, 2000; Yang et al., 2012). 80 
The poor permeation properties of imiquimod deeper into the skin is attributed to the various 81 
physiochemical properties of the drug. It is suggested some of the ideal characteristics for a drug to 82 
permeate deeper into the skin include a Mw < 600 Da, a Log P 1.0 to 3.0, a low melting point, and ≤2 83 
hydrogen bonding groups (Sabri et al., 2019). Although imiquimod meets some of these criteria, the 84 
drug has a high melting point of 292 °C and a total of 4 hydrogen bonding groups. The presence of 85 
such hydrogen bonding groups, especially the primary amine that may interact with the anionic 86 
components of the stratum corneum, contribute to the poor permeation profile of imiquimod deeper 87 
into the skin (Al-Mayahy et al., 2019). Furthermore, the drug has poor aqueous solubility which 88 
precludes the drug from permeating deeper into the aqueous and water rich dermal layers (Sabri et 89 
al., 2020) .The combination of these factors presents a challenge in delivering imiquimod in a 90 
concentrated and localised fashion into the dermis for the treatment of nodular BCC.  91 
It has been reported by patients that topical treatment such as creams are often unfavorable as this 92 
drug delivery vehicle typically has poor cosmetic feel upon administration as well as exuding an 93 
unpleasant scent once applied. In addition, the restriction in daily activities post application imposed 94 
after application (e.g. not being able to shower and bathe after application) may result in poor 95 
compliance (Devaux et al., 2012). Also, the likelihood of the cream spreading onto clothes and healthy 96 
skin also raises the issue of unwanted side effects.  97 
One of the drug delivery platforms that could be utilised to improve the delivery of imiquimod into 98 
the dermis for the management of basal cell carcinoma are microneedles. Microneedles consist of 99 
arrays of fine micro-projections that generate transient channels when applied to the skin. The 100 
accepted view is that microneedles breach the outermost layer of the skin, stratum corneum, 101 
generating channels which promote the entry of molecules into and across the skin (Prausnitz, 2004). 102 
Microneedles have been widely investigated as a drug delivery platform for skin cancer therapy, as 103 
such systems provide more localised delivery of therapeutics. In the context of skin tumours, 104 
microneedle-based drug delivery systems can locally mediate the release of drugs and increase their 105 
permeation into deeper tumour regions within the skin (Sabri et al., 2019). Several researchers have 106 
investigated the utility of using solid microneedles, as a skin pre-treatment via the patch-and-poke 107 
strategy, to improve the utility of delivering anticancer compounds into the skin for the treatment of 108 
skin cancer. Naguib et al. demonstrated, via a murine model, the feasibility of using solid stainless-109 
steel microneedles to enhance the intradermal delivery of 5-fluorouracil, 5-FU to treat skin tumours. 110 
In their in vitro work, the group demonstrated that 5-FU flux increased by 4.5-fold when 5-FU cream 111 
was applied on microneedle perforated murine skin compared to cream application on intact skin 112 
(Naguib et al., 2014). More recently, Al-Mayahy et al showed that using a two-step application process 113 
involving pre-treating the skin with solid stainless-steel microneedles followed by AldaraTM cream 114 
application, they were able to enhance the permeation of imiquimod deeper into the skin (Al-Mayahy 115 
et al., 2019).  116 
However, the utility of using solid stainless-steel microneedles is limited by the short duration (< 15 117 
min) than the channels remain open, due to the regeneration of skin, ultimately reducing the amount 118 
of drug delivered (Bal et al., 2010). Given these limitations of topical cream application, there is an 119 
impetus to reformulate imiquimod into a dissolving microneedle system which could offer a more 120 
effective and patient friendly treatment strategy for the management of nodular BCC. The simple and 121 
straightforward one-step application using dissolving polymeric microneedle patch loaded with 122 
imiquimod relative to the two-step application process via the patch-and-poke strategy using solid 123 
microneedles and AldaraTM may be a more preferred treatment option for patients. However, there 124 
are no studies to date that have evaluated improving the delivery of imiquimod into the dermis via 125 
the use of dissolving polymeric microneedles for the management of nodular BCC.  126 
The aim of this study is to fabricate and characterize polymeric microneedles as a drug delivery system 127 
to achieve the localised intradermal delivery of imiquimod for nodular BCC treatment. 128 
Polyvinylpyrollidone-co-vinyl acetate (PVPVA) microneedles loaded with imiquimod were developed 129 
through a microfabrication and micromoulding technique. PVPVA is a biocompatible polymer that is 130 
widely used in the pharmaceutical industry as a dry binder in tableting, as a film-forming agent in 131 
tablet coating, as well as a film-forming agent in topical drug delivery systems (Kolter and Flick, 2000; 132 
Patel et al., 2015). Besides that, being a derivative of PVP, PVPVA is a chemically and biologically inert 133 
polymer which obviates the issues of polymer-drug compatibility along with biological toxicity 134 
(Taresco et al., 2017; Teodorescu and Bercea, 2015). A series of experiments were performed to 135 
characterise the PVPVA microneedle formulation. In addition, an in vitro permeation study, using full 136 
thickness ex vivo porcine skin was used to evaluate imiquimod delivery into and across the skin. HPLC 137 
and ToF-SIMS analysis were utilised to illustrate the permeation and dermal distribution of imiquimod 138 
into skin following the application of imiquimod loaded microneedles versus Aldara™ cream. This 139 
study can serve as a basis for future in vivo and clinical studies with imiquimod loaded PVPVA 140 
microneedles for nodular BCC treatment. 141 
2. Materials and Methods 142 
2.1. Materials 143 
Imiquimod was purchased from Cayman Chemicals, USA. Aldara™ topical cream (5% w/w imiquimod), 144 
MEDA Company, Sweden was purchased from Manor pharmacy, UK. Polyvinylpyrollidone-co-vinyl 145 
acetate (PVPVA), was kindly provided by BASF (Ludwigshafen, Germany). Polyethylene glycol, PEG 400 146 
was purchased from Sigma Aldrich, Belgium. Sodium carboxymethyl cellulose, Mw 90,000 was 147 
purchased from Sigma Aldrich, USA. Glycerol was purchased from Sigma Aldrich, USA. Sodium acetate 148 
was purchased from Sigma-Aldrich, UK. Acetonitrile (HPLC grade) and glacial acetic acid were obtained 149 
from Fisher Scientific, UK. Teepol solution (Multipurpose detergent) was ordered from Scientific 150 
Laboratory Supplies, UK. D-Squame standard sampling discs (adhesive discs) were purchased from 151 
Cuderm corporation, USA. OCT media was obtained from VWR International Ltd. Belgium. Deionised 152 
water was obtained from an ELGA reservoir, PURELAB® Ultra, ELGA, UK. All reagents were of analytical 153 
grade, unless otherwise stated. Ex vivo porcine skin was used in imiquimod permeation studies due to 154 
the similarities in histology, thickness and permeability to human skin (Benech-Kieffer et al., 2000). 155 
Skin samples were prepared from ears of six-month-old pigs obtained from a local abattoir prior to 156 
steam cleaning. The skins were of full skin thickness to prevent altering the biomechanical properties 157 
of the tissue that may lead to over-penetration of the microneedles into the skin (Naguib et al., 2014). 158 
The porcine skin samples were stored at -20 °C until analysis. 159 
2.2. Design and production of microneedle master structure and microneedle 160 
PDMS moulds 161 
To produce the custom PDMS moulds, a stainless-steel microneedle master structure was designed in 162 
SolidWorks 2018 (Dassault Systèmes), consisting of a 10 x 10 array of 300 µm x 300 µm x 1000 µm (W 163 
x L x H) pyramidal microneedles with tip-to-tip spacing of 800 µm. This master structure, and a 164 
corresponding mould housing, Figure S1, were then produced from stainless-steel using a Kern Evo 165 
CNC Micro Milling Machine at the University of Nottingham Institute for Advanced Manufacturing. A 166 
polydimethylsiloxane (PDMS) (Sylgard 184®, Dow Corning, Midland, MI) mould was then created from 167 
the stainless-steel microneedle master structure. A mixture of elastomer and curing agent, Sylgard 168 
184®, were prepared at a ratio of 10:1 (elastomer: curing agent). The mixture was then degassed for 169 
45 minutes to remove any trapped air in the mixture. After degassing the PDMS mixture was poured 170 
into the stainless-steel master mould structure and placed in an 80 oC oven for one hour to cure the 171 
PDMS. After curing, the mould along with the cured PDMS was plunged into an ice bath to allow ease 172 
of removal of the cured PDMS mould. The stainless-steel master structure was then cleaned with 173 
propan-2-ol before being reused to make further PDMS moulds. 174 
2.3. Fabrication of blank and drug loaded polyvinylpyrrolidone-co-vinyl acetate 175 
(PVPVA) microneedles 176 
Polymeric microneedles were prepared using a micromolding technique. The PDMS moulds produced 177 
as described in Section 2.2 were used to fabricate the blank microneedles. The microneedle matrix 178 
was prepared using 16.2 % w/v PVPVA (in water) by dissolving the polymer at room temperature and 179 
pressure for one hour. Then, 2% v/v of PEG 400 was added to the polymer solution. The polymer 180 
solution was then degassed for 30 minutes and 150 µl of the PVPVA solution was then pipetted using 181 
a positive displacement pipette into the PDMS mould and centrifuged at 4000 RPM for 15 min at room 182 
temperature to fill the needle cavities. Then, excess polymer was removed before leaving the needle 183 
layer to dry overnight in a desiccator. The backing layer of the microneedle patch were prepared using 184 
5.2 % w/w of carboxymethylcellulose, CMC (in water). The backing solution was made by dissolving 185 
CMC under stirring at 75 oC for 2 hours. In addition, 0.66 % v/w of glycerol was added to the backing 186 
solution as a plasticiser.  Using a positive displacement pipette, 200 µl of the CMC solution was then 187 
pipetted on top of the needle layers and centrifuged at 3500 RPM for 10 minutes. The mould was 188 
dried at room temperature for 48 hours in a desiccator. The polymeric microneedles were then 189 
demoulded and stored in a desiccator until further use. For imiquimod loaded microneedles the 190 
fabrication process was repeated in a similar fashion and composition, however the drug, PEG 400 191 
and PVPVA were dissolved in 0.05 M of hydrochloric acid under stirring for 1 hour. 192 
2.4. Characterisation of PVPVA microneedles (SEM, tensile strength, skin insertion 193 
properties) 194 
2.4.1. Microscopy 195 
Polymeric microneedle images were captured using an optical microscope (Zeiss Axioplan, Germany) 196 
and an environmental scanning electron microscopy (ESEM) (FEI Quanta 650) in low vacuum mode to 197 
visualize the shape and dimensions of the microneedles. For ESEM imaging, the microneedles were 198 
mounted on a metal stub using double-sided carbon tape prior to imaging. 199 
2.4.2. Measurement of needle fracture force 200 
The needle fracture force of the polymeric microneedles was determined using a texture analyser 201 
(Stable Microsystems, UK) following a previously reported method (Donnelly et al., 2011). This is to 202 
investigate the effect of applying an axial force parallel to the microneedle vertical axis, similar to the 203 
force encountered by the needles during application to the skin.  The polymeric microneedles were 204 
visually inspected before and after application of the compression force. For this, the force required 205 
for compression of the polymeric microneedle to a specified distance was measured. The polymeric 206 
microneedles were attached to a 10 mm cylindrical Delrin probe (part code P/ 10) using double-sided 207 
adhesive tape. The probe is connected to a 50-kg load cell and was set at the same distance from the 208 
platform for all the test measurements. The TA XT Plus Texture Analyser was set to compression, the 209 
pre-test speed was set at 2 mm/s and post-test speed at 10 mm/s. The trigger type was set to auto 210 
(force) with a trigger force of 0.009 N. The test station compresses the polymeric microneedle against 211 
a flat block of aluminium of dimensions 10.0 × 9.0 cm. Compression force versus displacement curves 212 
were plotted to calculate the fracture force. A total of five microneedle patches were used to evaluate 213 
the fracture force of the microneedles. 214 
2.4.3. In vitro skin simulant insertion 215 
As an alternative method to determine the microneedle penetration depth as a function of length, a 216 
polymeric film (Parafilm M®, a blend of a hydrocarbon wax and a polyolefin) was utilised as a skin 217 
model. This insertion study was adopted from Larrañeta et al.  (Larrañeta et al., 2014). In brief, 8 layers 218 
of Parafilm M® were stacked onto each other on a cork mat that mimics underlying muscles. The 219 
PVPVA microneedle patch was applied under thumb pressure for 10 seconds. Six replicates were 220 
generated and observed under the Zeta Profilometer (KLA-Tencor, US) for the number of micropores 221 
created.  222 
2.4.4. Dye binding study 223 
In order to evaluate if the microneedle patch is capable of penetrating the skin and to visualise the 224 
depth of microneedle penetration into the skin, a dye binding study using ex vivo porcine skin was 225 
conducted. The porcine ear skin was defrosted at room temperature for an hour prior to the 226 
experiment. Using clippers, excess hair was carefully trimmed from the skin.   Regions of the skin were 227 
then selected for microneedle treatment. The skin was treated with PVPVA microneedles loaded with 228 
methylene blue dye, which is a hydrophilic dye. The microneedle was left in the skin for one hour 229 
before removing the microneedle patch. Upon removing the patch, the skin was visually inspected to 230 
see if any microneedle channels have been generated in the skin. In order to gauge the depth of 231 
microneedle penetration into the skin, skin cross-sectioning was performed. In brief, each 232 
microneedle application site was cut into 1 cm × 1 cm and fresh frozen on a metal block that was 233 
cooled with liquid nitrogen. Skin cross-sections were performed using a cryostat (Leica CM3050 S 234 
Research Cryostat, UK). The depth of microneedle penetration as visualised by methylene blue 235 
permeation was measured using an optical microscope (Zeta Profilometer, KLA-Tencor, US). 236 
2.5. Measurement of imiquimod permeation from PVPVA microneedles 237 
Imiquimod skin permeation was evaluated ex vivo using a Franz-type diffusion cell. Prior to the 238 
permeation study, skin samples were defrosted and carefully trimmed into small pieces according to 239 
the area of the donor chamber of the Franz diffusion cell (Soham Scientific, Cambridgeshire, UK). The 240 
ex vivo porcine skins were subjected to the following treatments: i) application of 20 mg Aldara™ 241 
cream. This is in accordance with clinical dose approved by the FDA for the treatment of BCC. ii) 242 
imiquimod loaded PVPVA microneedles. Next, the treated porcine skins were placed on top of the 243 
receptor compartment filled with 3 ml of degassed 100 mM acetate buffer pH 3.7. This buffer was 244 
chosen as the receptor phase in order to maintain sink conditions throughout the permeation study. 245 
This is due to the insolubility of imiquimod at neutral or basic pH values. Various researchers have 246 
reported using acetate buffer pH 3.7 as the receptor phase in imiquimod permeation studies (Donnelly 247 
et al., 2006; Sharma et al., 2019; Venturini et al., 2015). The skin was then secured between the donor 248 
and receptor compartment of the diffusion cell using a metal clamp, with the stratum corneum side 249 
facing the donor compartment. Upon assembling the Franz diffusion cell, the permeation experiment 250 
was conducted over a period of 24 hours in a thermostatically controlled water bath set at 36.5 oC. 1 251 
ml of the receptor fluid at designated time points (0.5, 1, 3, 6, 12 and 24 hours) was sampled and then 252 
replaced with equal volume of fresh 100 mM acetate buffer pH 3.7.  Upon sampling, 1000 µl of the 253 
solution from each Franz cell after collection was then spiked with 100 µl of 100 µg/ml propranolol as 254 
an internal standard before being filtered through 0.22 µm membrane prior to HPLC analysis. 255 
After the 24-hour permeation experiment, the excess cream was removed from the AldaraTM cream 256 
treated skin surface by careful application of sponges soaked with 3% v/v Teepol® solution. For the 257 
microneedle patch treated skin, the remaining microneedle patch was removed from the skin. Upon 258 
removing excess formulation from the skin surface, 15 sequential tape strips were collected from the 259 
skin. The amount of imiquimod from the pooled tape strips and remaining skin after tape stripping 260 
were extracted by the addition of 10 and 5 mL of methanol extraction mixture (Methanol 70%: Acetate 261 
Buffer pH 3.7 100 mM 30%) respectively using a previously reported method (Paula et al., 2008). 262 
Samples were then vortexed for 1 minute and sonicated for 30 minutes before being left overnight. 263 
Subsequently, samples were vortexed again and sonicated for a further 30 minutes.  264 
After sonication, 1000 µl of the extracts were collected and spiked with 100 µl of 100 µg/ml 265 
propranolol as an internal standard. The samples were then filtered through 0.22 µm membrane prior 266 
to HPLC analysis. 267 
2.6. High performance liquid chromatography (HPLC) analysis 268 
HPLC analysis was carried out using an Agilent 1100 series instrument (Agilent Technologies, Germany) 269 
equipped with degasser, quaternary pump, column thermostat, autosampler and UV detector. System 270 
control and data acquisition were performed using Chemostation software. The details of the HPLC 271 
chromatographic conditions are as follow: column C18 (150 × 4.6 mm) ACE3/ACE-HPLC Hichrom 272 
Limited, UK. The mobile phase composition for analysis of extracts from skin wash, donor chamber 273 
wash, pooled tape strips and remaining skin consists of 10 mM acetate buffer: acetonitrile (79:21). 274 
Whilst, the mobile phase composition for analysis of receptor fluid consists of 10 mM acetate buffer: 275 
acetonitrile (70:30). The HPLC was operated at a flow rate of 1.0 mL/minute, UV detection at λ 276 
max=226 nm, an injection volume of 40 µL and a column temperature of 25 °C.   277 
2.7. ToF-SIMS analysis of skin cross-sections 278 
In order to evaluate the depth of imiquimod permeation into the skin, the permeation experiments 279 
were repeated as described above Section 2.5. After the permeation study, excess formulation was 280 
removed from skin samples treated with cream and microneedles. Then, 1 cm × 1 cm of each 281 
application site was fresh frozen with liquid nitrogen. Skin cross-sectioning was performed using a 282 
cryostat (Leica CM3050 S Research Cryostat, UK). The skin slices were then thaw mounted on a glass 283 
slides and stored at -20 oC prior to ToF-SIMS analysis. ToF-SIMS was used to analyse the cryo-sectioned 284 
porcine skin samples. ToF-SIMS analysis was performed using a ToF-SIMS IV instrument (IONTOF, 285 
GmbH) with a Bi3+ cluster source. A primary ion energy of 25 KeV was used, the primary ion dose was 286 
preserved below 1 × 1012 per cm2 to ensure static conditions. Pulsed target current of approximately 287 
0.3 pA, and post-acceleration energy of 10 keV were employed throughout the sample analysis. The 288 
mass resolution for the instrument was 7000 at m/z 28.  289 
2.8. Statistical analysis 290 
Statistical analysis was conducted using GraphPad Prism 7.02 software. Data are shown as 291 
mean ± standard error of mean. When comparing two groups an unpaired t-test analysis was used, 292 
while one-way analysis of variance (ANOVA) with Tukey's multiple comparisons tests was used to 293 
compare multiple groups. P values < 0.05 were considered statistically significant. 294 
3. Results and Discussion 295 
3.1. Microneedle fabrication 296 
In this work, polymeric PVPVA microneedles of pyramidal geometry were fabricated through four 297 
manufacturing stages; structure design via CAD, micromachining, PDMS mould production and casting 298 
as shown in the schematic of Figure S1. Micro-milling was used to fabricate the designed stainless-299 
steel master structures with minimal surface imperfections as evidenced in Figure S1. Micro-milling 300 
was used as the technique enables simplicity in the design process while offering low manufacturing 301 
cost in generating complex geometry with high accuracy and repeatability (García-López et al., 2018).  302 
Next, the PDMS moulds were produced by micromoulding followed by microneedle patch fabrication 303 
via casting, centrifugation and drying. The resulting polymeric microneedle patch is shown in Figure 1. 304 
Upon visual inspection as shown in Figure 1 (a), we found that the microneedle array consists of 100 305 
uniformly distributed pyramidal microneedles. Each microneedle array had a slightly opaque and off-306 
white appearance. The microneedle patch displays micro projections, pyramidal in structure with a 307 
length of 992.3 ± 45.3 µm (mean ± SD, n=10) and a tip diameter of 32.3 ± 3.1 µm (mean ± SD, n=4) as 308 
visualised by optical microscopy images shown in Figure 1 (b) and (c). With regards to the production 309 
method used in this study, which involved centrifugation and micromoulding, such methodology is 310 
most suited for lab-based research. However, this method of microneedle fabrication would not be 311 
ideal for the manufacture of patches at a commercial scale. However, the use of aqueous drug-312 
polymer blend casting could be potentially be translated into the scalable roller system manufacturing 313 
method developed by Lutton et al (Lutton et al., 2015). The use of the roller system manufacturing 314 
method would provide a potential scale-up manufacturing method at a commercial scale, enabling 315 
the transition from laboratory to industry and subsequent clinical practice.  316 
 317 
Figure 1  a) Photograph image of PVPVA microneedles post-fabrication (b) Optical microscopy image of PVPVA microneedles 318 
at 12.5x magnification (c) close up microscopy image - of a single PVPVA polymeric microneedle at 50x magnification (d) SEM 319 
images of PVPVA microneedles at 39x magnification. 320 
 321 
An analysis by SEM, as shown in Figure 1 (d), revealed equally spaced, sharp pyramidal microneedles, 322 
on a clean and smooth base. This clearly indicates that the copolymer PVPVA was a suitable material 323 
for fabricating polymeric microneedles. Although, PVPVA has not been used previously for 324 
microneedle fabrication, the homopolymer PVP has been widely used. In addition, the hydrophilic 325 
nature of both of these polymers makes it easy to use them for fabricating microneedles via casting 326 
and micromoulding aqueous solutions of the polymers into the PDMS moulds. This overcomes the 327 
need for organic solvents which could damage the PDMS moulds with repeated use (Mahomed et al., 328 
2010). Previous work has shown that PVP microneedles are capable of delivering a range of 329 
therapeutics such as sumatriptan, polymyxin B, atorvastatin, aspirin, and lisinopril  (Dillon et al., 2017; 330 
Quinn et al., 2015; Ronnander et al., 2018). In addition, although PVPVA has never been used 331 
previously in microneedle fabrication, the extensive biocompatible and cytocompatible data on the 332 
polymer strongly suggest that the PVPVA microneedles are safe for this biomedical application 333 
(Moore, 1983). 334 
Preliminary microneedle fabrication without the use of PEG 400 as a plasticiser resulted in 335 
microneedles with fractured tips as shown in Figure S2. A lack of consistency in microneedle length 336 
and tip formation may result in complications such as failure to penetrate the skin as well as 337 
inconsistent drug release from the individual microneedles within the same patch. The presence of 338 
fractured tips is attributed to the formation of brittle polymeric microneedles post-drying. The 339 
brittleness of the preliminary PVPVA microneedles was due to the high Tg of the polymer at 107 oC as 340 
shown in Figure S3.  Since the microneedles were demoulded at room temperature, the polymer is 341 
well below its Tg and is in glassy and brittle state making it prone to fracture (Aulton, 2011). In order 342 
to overcome this issue, PEG 400 was introduced into the needle matrix as a plasticiser. The use of PEG 343 
400 falls under the category of an external plasticiser which has been used in several other 344 
microneedle formulations (Dillon et al., 2017; Quinn et al., 2015; Sun et al., 2013).  345 
Due to the rigid but brittle nature of PVPVA, we discovered that using the same PVPVA and PEG 400 346 
polymer solution as a backing layer resulted in microneedle patches that fractured during the 347 
demoulding stage as shown in Figure S4. A microneedle backing layer ought to be flexible to enable 348 
easy demoulding while allowing the microneedle patch to adapt to the skin curvature during 349 
administration (Xue et al., 2015). In order to meet these criteria, we used a different polymer blend 350 
consisting of CMC and glycerol to fabricate the backing. CMC is one of the most commonly polymer 351 
solutions used in fabricating the backing layer of microneedle patches (McGrath et al., 2014; Park et 352 
al., 2016).  353 
3.2. Microneedle characterisation 354 
The mechanical properties of the needles were determined using a texture analyser. The polymeric 355 
microneedle arrays were subjected to an axial compression test to measure the fracture force of the 356 
polymeric microneedles. Profiles of force versus displacement (analogous to stress-strain curves), 357 
based on average force values (n = 5), were generated for the PVPVA polymeric microneedle patch. 358 
This force versus displacement curve was then used to determine the average fracture force per 359 
needle.  From the microneedle fracture test, the PVPVA microneedles displayed a fracture force of 360 
0.106 ± 0.003 N/needle (mean ± SD, n=5). The required fracture force that microneedles need to 361 
possess in order to puncture the skin without fracturing is 0.098 N/needle (Lee et al., 2015; Yu et al., 362 
2017). In addition, Donnelley et al. has even reported successful skin insertion with microneedles that 363 
possess a fracture force as low as 0.03 N/needle (Donnelly et al., 2012). Therefore, it can be inferred 364 
that the fabricated microneedles displayed sufficient mechanical strength above the reported 365 
threshold needed to puncture the skin without fracturing. 366 
It is of great importance that fracture test is coupled to insertion studies in order to evaluate the 367 
penetration capability of the fabricated microneedles. The insertion of PVPVA microneedle patch into 368 
a stack of Parafilm® layers was used as an in vitro skin model. This was performed by applying the 369 
patches onto the Parafilm® stacks under thumb pressure. Upon application, each Parafilm layer was 370 
separated and visualised using an optical microscope to evaluate the pore uniformity as a function of 371 
penetration depth. Figure 2 (a) shows that square shaped pores, which follows the shape of the square 372 
pyramidal PVPVA microneedle, were created on the Parafilm layers upon microneedle patch 373 
application. In addition, it can be seen that the number of microneedle channels generated decreased 374 
as a function of Parafilm layer number with the deepest layer penetrated by the microneedle patch 375 
being the fourth layer as shown in in the insertion profile of Figure 2 (b). In addition, it was apparent 376 
that all replicates resulted in complete microneedle insertion in the first parafilm layer as shown in 377 
Figure 2 (b). The Parafilm® insertion test was developed by Larrañeta et al as an in vitro test to predict 378 
the insertion capabilities of microneedles in actual skin tissues (Larrañeta et al., 2014). Collectively, 379 
Figure 2 (a) along with the insertion profile from Figure 2 (b), suggests that fabricated PVPVA 380 
microneedle patch is capable breaching the stratum corneum permitting microneedle insertion into 381 
the skin. 382 
 383 
Figure 2 (a) Microscopic images of first Parafilm® treated by PVPVA microneedles (b) Insertion profile of PVPVA microneedle 384 
into Parafilm® layers (c) Microchannels created in ex vivo porcine skin visualised via the release of methylene blue from 385 
PVPVA microneedles (d) Optical microscopy image of microneedle channels  created when the skin is treated with PVPVA 386 
microneedles  387 
A dye release study was then performed to evaluate the ability of the microneedle patches to puncture 388 
the skin. Methylene blue loaded microneedle patch was applied onto porcine cadaver skin, which 389 
upon application resulted in the release of the hydrophilic dye to the surrounding skin tissue upon 390 
PVPVA dissolution. This results in the formation of blue microneedle channels within the porcine skin 391 
that follows the distribution of PVPVA microneedles on the patch as shown in Figure 2 (c). The 392 
histological image of the vertical section of microneedle treated skin, shown in Figure 2 (d) provides 393 
an estimate into the depth of microneedle penetration into the skin. The application of PVPVA 394 
microneedles loaded with methylene blue breached the stratum corneum and epidermis layers as 395 
shown in Figure 2(d). The average depth of microneedle penetration was 426 ± 72 µm (mean ± SD, 396 
n=10). The penetration depth of the microneedles are of approximately the same depth as that 397 
observed with the Parafilm insertion study. With regards to clinical translation of the technology, 398 
reproducible insertion of microneedles by patients and carers is an important factor to consider. 399 
Various strategies have emerged over the years to ensure effective and reproducible insertion of 400 
microneedle patches into the skin. One of the strategies could be the use of microneedle applicators. 401 
Some examples of the microneedle applicator that could be used include MicroCorTM and Macroflux® 402 
(Singh et al., 2011). Alternatively, the use of pressure-indicating sensor film such as Pressurex-micro® 403 
Green may be an alternative, might be an option in providing feedback to patient and carers that they 404 
had pressed the microneedle with sufficient force into the skin (Vicente-pérez et al., 2016) 405 
It was apparent that the microneedle penetration depth into ex vivo skin was shorter than the length 406 
of the microneedle. This observation agrees with earlier findings by Martanto et al. who reported 407 
partial microneedle insertion into the skin (Martanto et al., 2006). Such an observation is attributed 408 
to the inherent elastic nature of the skin which resists microneedle penetration. However, since it has 409 
been reported that the thickness of the porcine epidermal layer varies between 30-140 µm (Branski 410 
et al., 2008) it can be seen that from the vertical cross-sectional data Figure 2 (a) the microneedle 411 
application in this case has reached the skin dermis. In comparison, the human skin is reported to have 412 
an epidermal thickness of 800-1500 µm for thick skin (palm of the hands and sole of the feet) and 70-413 
150 µm for thin skin (face, eye lids, neck and arm) (Albanna and Holmes IV, 2016).  Importantly in this 414 
instance, as BCC mainly manifests on thin skin surfaces such as the face, neck and eyelid (Carr et al., 415 
2018), it can be postulated that application of the PVPVA microneedle patch would bypass the 416 
epidermis and reach the dermis which is the target site for the treatment of nodular BCC. Besides that, 417 
in regions where there are curvatures such as the facial cheeks, nose and eyelids the application of 418 
microneedle would still be viable. However, in this instance, the use of a very flexible backing layer 419 
such as those fabricated from polyethylene glycol diacrylate (PEGDA) would allow the microneedle 420 
patch to adapt to skin curvature whilst permeating effective skin insertion (Xue et al., 2015). 421 
The hygroscopic nature of PVPVA could have an adverse effect on the needle architecture along with 422 
its insertion capabilities on long term storage. Hence in order for this technology to be translated into 423 
clinical practice stability studies will need to be carried out to verify the needle structure. With respect 424 
to the hygroscopicity of PVPVA, relative to PVP which is widely used in microneedle research, PVPVA 425 
is less hygroscopic that PVP. The work by Shamblin and Zografi showed that the amount of water 426 
absorbed by PVPVA was one-third of that absorbed by PVP when stored at humidity levels similar to 427 
that of ambient room conditions. Such an observation is attributed to the carbonyl group of the vinyl 428 
acetate moiety which is less basic and hence less prone to hydrogen bonding than the carbonyl group 429 
in the pyrrolidone ring (Shamblin and Zografi, 1999). Therefore, the use PVPVA which is a less 430 
hygroscopic polymer than the widely used PVP, may produce microneedles which are less susceptible 431 
to moisture than the commonly fabricated PVP microneedles. Nevertheless, one of the manufacturing 432 
and distribution challenges will be the need to manufacture, distribute and store the microneedles in 433 
a low humidity environment to reduce the exposure to moisture that may affect the architecture of 434 
the needle and ultimately the insertion of the needle into the skin. One possible suggestion to 435 
overcome this is to pack the microneedle patches in nitrogen flushed sterile packets that demonstrate 436 
protection against water ingress.   437 
Considering the fact that microneedle dosage forms penetrate the stratum corneum rather than 438 
adhere to the surface of the skin as in a conventional transdermal patch, sterility will potentially be a 439 
key requirement by regulatory bodies. Previous work by Mccrudden et al 2014 have shown that 440 
endotoxin levels in dissolving microneedles can achieve levels below set by the Food and Drug 441 
Administration (FDA) guidelines for medical devices that are in direct contact with lymphatic tissue 442 
(20 units/device) using the appropriate sterilisation techniques (Mccrudden et al., 2014).   As PVPVA 443 
microneedles may be susceptible to moisture due to the hygroscopic nature of polymeric 444 
microneedle, the use of heat/steam sterilisation may damage this type of microneedle necessitating 445 
microneedle production under aseptic conditions. The use of gamma irradiation may be an 446 
alternative, however previous work has shown that this method of terminal sterilisation alters the 447 
release profile of dissolving microneedles (Mccrudden et al., 2014). 448 
3.3. Drug release study from PVPVA microneedles 449 
3.3.1. HPLC analysis  450 
In vitro permeation studies utilising Franz diffusion cells are widely used to study the intradermal and 451 
transdermal delivery of drugs across the skin. In this work, we investigated the delivery of imiquimod 452 
from drug loaded microneedle patches into and across the skin in comparison to the commercial 453 
imiquimod cream, AldaraTM. Imiquimod was loaded into the microneedles by dissolving both the 454 
polymer (PVPVA) and the drug into a polymer blend, casting the solution into the PDMS micromoulds, 455 
centrifugation and finally drying. Imiquimod-loaded polymeric PVPVA microneedles dissolved 456 
gradually in a limited volume of the skin’s interstitial fluid to release drug into and across the skin 457 
layer. It was apparent that both drug delivery systems were capable of delivering imiquimod into the 458 
stratum corneum, remaining skin and into the receptor fluid as shown in Figure 3. 459 
From Figure 3 (a) we observed that the mean amount of imiquimod delivered into the stratum 460 
corneum as evidenced from HPLC analysis of tape strips are 23.2 µg for microneedle treated and 8.6 461 
µg for AldaraTM cream treated skins. The differences in amount of imiquimod delivered into the 462 
stratum corneum was of statistical significance (p<0.05). Such enhanced permeation into the stratum 463 
corneum with imiquimod loaded microneedles may be attributed to the generation of microneedle 464 
channels within the skin. These channels act as focal points for imiquimod to permeate laterally and 465 
localise to the surrounding corneocytes, thus enhancing delivery to the upper layer of the skin.  466 
 467 
Figure 3 Amount of drug extracted from skin (tape strips and remaining skin) after 24 hours in the permeation study. Drug 468 
concentration within receptor fluid as a function of time during permeation study from AldaraTM and imiquimod microneedles. 469 
Data are expressed as mean± SEM for n=6. Differences were calculated using one-way ANOVA, followed by Tukey’s post hoc 470 
test, and deemed significant at p<0.05. n.s = not statistically significant at p>0.05 471 
However, in the case of nodular BCC the drug delivery system must be capable of delivering the drug 472 
beyond the stratum corneum and deeper into the skin (Williams et al., 2017). Therefore, in order to 473 
gauge the amount of drug delivered deeper into the skin, HPLC analysis was conducted on remaining 474 
skin after tape stripping. Figure 3 (a) also shows that the mean amount of imiquimod delivered into 475 
the remaining skin from both treatment groups. It was observed that the amount drug extracted from 476 
the remaining skin treated with the microneedles was lower than the amount of drug delivered by the 477 
commercial cream, AldaraTM although such differences were not statically significant (p>0.05). This 478 
would suggest that the overall amount delivered per application of both delivery system are similar. 479 
From a dose delivered perspective, it may appear that the microneedle patch does not offer any 480 
additional benefits. However, when the two systems are viewed in terms of ease of application, the 481 
microneedle patch offers a simple one-step application to insert the microneedles into the skin under 482 
thumb pressure. This avoid the issues of dosing accuracy with the amount of cream applied and 483 
problems associated with the cream spreading to non-diseased skin which are associated with 484 
AldaraTM cream. With regards to the amount of imiquimod delivered for the management of BCC, it 485 
would be more preferable to use the AldaraTM cream in the management of superficial BCC as we 486 
would mitigate the unnecessary exposure of underlying healthy skin tissue to imiquimod.  However, 487 
given the fact that at least one-third of nodular BCC coexist with superficial BCC (Goldenberg et al., 488 
2010), the use of imiquimod loaded microneedles in such instances would be useful as the drug could 489 
deliver equal amounts of imiquimod to tumour located at the skin surface and underlying skin tissues. 490 
In addition, Figure 3 (b) shows the amount of imiquimod delivered into the stratum corneum and 491 
remaining skin when calculated as a percentage of the applied dose. In this instance the percentage 492 
of the drug successfully delivered into the stratum corneum and remaining skin is significantly higher 493 
with imiquimod microneedles than that of AldaraTM cream. The drug loading in the microneedle patch 494 
was 165.6 ± 21.4 µg (mean ± SD, n=8). Whilst, ≈20 mg of Aldara cream (1000 µg of imiquimod) was 495 
applied to the skin area of 3.8 cm2, in the Franz cell, which is based on clinical dose for AldaraTM cream 496 
for the treatment of BCC (FDA, 1997).  Figure 3 (b) highlights that we are able to deliver similar 497 
amounts of imiquimod into the remaining skin using a different delivery system despite a 6-fold lower 498 
drug loading with the microneedle patch. 499 
 500 
Figure 3 (c) shows the concentration of imiquimod detected in the receptor fluid over time. It can be 501 
seen that the concentration of imiquimod in the receptor fluid overtime, was similar between AldaraTM 502 
cream and imiquimod microneedle treated skin for up to 12 hours. However, at 24 hours, the 503 
concentration of imiquimod within the receptor fluid is less for skin treated with imiquimod 504 
microneedles relative to AldaraTM cream. This highlights that over the course of 24 hours, the 505 
microneedle patch resulted in less imiquimod delivery across the skin while delivering similar quantity 506 
of the drug into the remaining skin.  It is understood the amount of drug detected in receptor fluid 507 
following an in vitro Franz cell permeation study  provides a an indicator on the likelihood of systemic 508 
exposure  (Benson and Watkinson, 2011).  Hence, it could be postulated that the likelihood for 509 
systemic exposure to imiquimod following microneedle treatment is lower in comparison to AldaraTM 510 
application. This may limit the likelihood of influenza-like symptoms, an undesirable side effect 511 
associated with imiquimod systemic exposure (Rossi et al., 2012).  Based on the current work, it is 512 
suggested that the microneedle is left in the skin for 24 hours to allow comparative application and 513 
delivery of imiquimod into the skin as to that of AldaraTM cream. In terms of practical delivery of 514 
imiquimod using microneedle relative to other route of administrations such as oral delivery, a 515 
microneedle based intradermal delivery would be more practical as it enables more targeted delivery 516 
and avoids the likelihood of systemic side effects arising from oral delivery of imiquimod which could 517 
give rise to flu-like symptoms and result in a poor overall quality of life for the patient. 518 
In terms of enhancing imiquimod permeation, several groups have considered alternative drug 519 
delivery systems such as the use of an emulsion gel (Stein et al., 2014), transethosomes (Ma et al., 520 
2015) and a hydrogel/oleogel colloidal mixture (Rehman et al., 2015).  However, these types of 521 
formulations are typically associated with poor sensory and cosmetic issues (e.g. tackiness and 522 
stickiness) upon application. In addition, these semisolid dosage forms could potentially stain patients’ 523 
clothes as well as spread to healthy skin regions leading to unwanted side effects (Buchmann, 2005; 524 
Devaux et al., 2012). This may ultimately limit patient compliance to the overall treatment.  These 525 
limitations are not encountered with microneedle formulations as the patches are anchored in place 526 
by the micro-projections ensuring precise localised delivery at the site of application. In addition, with 527 
regards to disposal of the patch upon skin insertion, as the PVPVA microneedles are dissolving 528 
microneedles, the microneedles will dissolve in the skin leaving behind the backing layer. Therefore 529 
the microneedle patch is self-disabling post-insertion overcoming the issues of dangerous sharp waste 530 
disposal in resource-poor settings (González-vázquez et al., 2017). 531 
3.3.2. ToF-SIMS analysis 532 
 It was apparent that HPLC analysis provided quantitative results that permit us to compare the 533 
delivery efficiency of both formulations. However, HPLC does not provide any spatial information 534 
pertaining to the dermal distribution of imiquimod. In order to complement the HPLC data, ToF-SIMS 535 
was utilised to provide insight into the dermal distribution of imiquimod.  536 
Figure 4 shows ToF-SIMS secondary ion images from skin cross-sections analysed after a 24-hour 537 
permeation study. Due to the parallel detection capabilities of the ToF-SIMS, secondary ions 538 
originating from both the skin tissue, polymer and drug were detected and analysed. By carefully 539 
monitoring the ion peaks from the ToF-SIMS spectra (Figure S5), we are able to visualise the 540 
localisation and distribution of these secondary ions. The fragment ion for phosphatidylcholine, 541 
C5H15NPO4+ was used to identify the dermis and viable epidermis. Additionally, the fragment ion for 542 
ceramide, C17H32N+ is utilised to distinguish the stratum corneum from the viable epidermis and dermis  543 
(Sjövall et al., 2014).  This is because, the stratum corneum displays high levels of ceramide whilst 544 
being devoid of phospholipids which makes C17H32N+ a good marker for the stratum corneum  (Elias, 545 
2005; Starr et al., 2019). In a previous work, it has been found that the permeation of the imiquimod 546 
across the skin could be tracked by monitoring the molecular ion C14H17N4+ (Al-Mayahy et al., 2019). 547 
Through monitoring the fragment ion peak C6H10NO+ we were able to detect the localisation of the 548 
PVPVA polymer within the microneedle channels as shown in Figure 4. The peak assignment for PVPVA 549 
was validated by referring to fragmentation pattern at m/z 112 with the reference spectra of pure 550 
PVPVA on silicon wafer as shown in the supplementary data (Figure S6). It is worth noting that, that 551 
the parallel detection capability of the ToF-SIMS also enabled the detection of Si+ marker -an inorganic 552 
ion of silicon -indicated in yellow in Figures S7 and S8 used to identify the glass slide (the substrate 553 
used to mount the cross-sections) as silicon is a common fundamental constituent of glass. Figures S7 554 
and S8 also shows the total ions image collected from the ToF-SIMS sample analysis. 555 
 556 
Figure 4 ToF-SIMS image of skin cross sections from ex vivo porcine skin that were treated with (i) AldaraTM cream (5% w/w 557 
imiquimod) alone (ii) PVPVA microneedles loaded with imiquimod after a 24-hour permeation study. Localisation of semi-558 
dissolved polymeric microneedles within the dermis with skin treated imiquimod loaded microneedles. C14H17N4+inidicated in 559 
green is the molecular ion for imiquimod, C5H15NPO4+ indicated in blue is the fragment ion for phosphatidylcholine used to 560 
identify the viable epidermis and dermis. C17H32N+ indicated in red is the fragment ion for ceramide used to identify the 561 
stratum corneum. C6H10NO+ indicated in pink is the fragment ion for PVPVA polymer. Scale bar: 500 µm 562 
It is apparent from Figure 4 (a) that there is limited availability of imiquimod within deeper skin strata 563 
when the molecule was delivered as a topical cream, AldaraTM. When the drug is applied as a topical 564 
cream, imiquimod is localised in the stratum corneum as evidenced from overlay of imiquimod 565 
molecular ion, C14H17N4+ with the fragment ion for ceramide, C17H32N+. However, when imiquimod is 566 
delivered as a polymeric microneedle patch, we observed delivery of imiquimod into the dermis within 567 
microchannels as shown in Figure 4 (b). It is clear from the ceramide fragment ion, C17H32N+ in  568 
Figure 4 (a) that the stratum corneum looks intact when the drug is administered as a topical cream.  569 
In contrast, when the drug is delivered as a polymeric microneedle patch, we observed disruption in 570 
the ceramide fragment ion, C17H32N+ distribution within top layer of the skin as shown in Figure 4 (b) 571 
that suggest that the microneedles have disrupt the stratum corneum permitting the insertion of the 572 
drug loaded polymeric microneedles into the skin. Typically nodular BCC are much harder to treat 573 
effectively as the tumour typically manifests 400 µm below the skin surface (Williams et al., 2017). 574 
The ToF-SIMS analysis of skin cross-sections from Figure 4 suggests that the microneedle patch 575 
penetrated the skin to a depth of approximately 450 µm resulting in imiquimod delivery into the 576 
dermis. With regards to penetrating the BCC tumours with microneedles, concerns may be raised on 577 
the likelihood of aggravating the tumour which may lead to unintended side effects. However, there 578 
is little to no clinical concerns with regards to penetrating BCC tumour as the tumours are routinely 579 
penetrated via punch biopsy and intraoperative incisional biopsy. Such surgical procedures do not lead 580 
to any localised or distant spread of the BCC tumour. In fact, microneedle insertions are minimally 581 
invasive, therefore the damage inflicted from penetrating the BCC tumour with microneedles is less 582 
relative to these routine surgical procedures. In addition, many BCC lesions are also frequently 583 
traumatised accidentally by patients which causes localised bleeding but again no serious 584 
consequences (Jung et al., 2012; Kamyab-Hesari et al., 2014).  585 
With regards to the dermal distribution of the various components of a microneedle system, several 586 
research groups have employed techniques such as fluorescently tagging the molecule of interest in 587 
order to visually track the delivery of compound into the skin (Saurer et al., 2010; Yu et al., 2017). This 588 
method results in modification of the physiochemical properties of the drug leading to potentially 589 
inaccurate estimation of drug permeation into the skin (Vasquez et al., 2011). However, there is no 590 
work in the field that has demonstrated the capability to simultaneously detect the deposition of both 591 
drug and polymer from a dissolving microneedle patch in a label free manner. ToF-SIMS analysis also 592 
provides the capability to perform parallel detection of both endogenous and exogenous chemistry 593 
present in the analysed samples, thus permitting simultaneous mapping the presence of polymer 594 
within biological tissues as well as the drug. The polymer that is used in fabricating the microneedle 595 
patch is PVPVA. Through monitoring the fragment ion peak at m/z 112 we were able to detect the co-596 
localisation of the polymer and imiquimod within the microneedle channels as shown in Figure 4.  597 
By comparing this finding with the ToF-SIMS analysis of skin cross-section from samples treated 598 
imiquimod loaded microneedles in Figure 4 (b), it was observed that imiquimod was colocalised in the 599 
presence of PVPVA polymer within the dermis following skin application. This leaves imiquimod which 600 
is embedded in a polymer matrix within skin. It has been previously postulated that embedded drug-601 
polymer matrix slowly undergoes dissolution; generating localised regions of enhanced viscosity 602 
within the skin that slows the rate of drug release to surrounding tissues (Chu and Prausnitz, 2011; 603 
Ribeiro et al., 2017). However, in the current work we are able to demonstrate via ToF-SIMS analysis 604 
the existence of such semi-dissolved polymeric regions within the dermis that retains drug from 605 
permeating across the skin and into the receptor fluid. From a clinical perspective, the reduction in 606 
imiquimod permeation across the skin may limit the likelihood of systemic side-effects.   The ability of 607 
a microneedle patch to deliver the drug to a desired location despite having lower drug loading may 608 
serve as a possible explanation for the dose sparing advantage conferred by microneedles. To the best 609 
of our knowledge, this is the first report of the dose sparing advantage conferred by microneedles for 610 
small molecule therapeutics.  611 
Although a PVPVA polymer depot was observed, there is evidence based on this commercial polymer’s 612 
Mw i.e 15-20 kDa that it would be eventually excreted. Indeed, based on the findings from Kagan et 613 
al on the elimination of macromolecules from the skin, it is estimated that a majority of the polymer 614 
will be drained into the dermal blood capillaries with some drainage into the dermal lymphatics before 615 
reaching the systemic circulation (Kagan et al., 2007). Furthermore, as the PVPVA has a Mw less than 616 
60 kDa, the polymer will be excreted through the kidneys once it reaches the systemic circulation 617 
(Hespe et al., 1977; Yamaoka et al., 1995). 618 
The HPLC analysis data for AldaraTM cream treated skin shown in Figure 3 (a) appears to contradict the 619 
ToF-SIMS analysis of skin cross-section with regards to amount drug delivered into the superficial layer 620 
of the skin, i.e. the stratum corneum. In order to elucidate this discrepancy, we performed a closer 621 
analysis of skin cross-sections of AldaraTM cream treated skin as shown in Figure 5. As discussed earlier, 622 
the fragment ion for phosphatidylcholine (C5H15NPO4+) was used to identify the dermis and viable 623 
epidermis while the fragment ion for ceramide, C17H32N+ is now utilised to distinguish the stratum 624 
corneum from the viable epidermis and dermis. Closer analysis of the AldaraTM cream treated skin 625 
showed that the majority of the molecule of interest, imiquimod resides within the stratum corneum. 626 
 627 
Figure 5 ToF-SIMS image of skin cross sections from porcine skin that were treated with AldaraTM cream (5% w/w imiquimod) 628 
alone. This analysis was conducted at a higher resolution closer to the skin surface to image the localisation of imiquimod  629 
near the stratum corneum and epidermis junction. C14H17N4+ the molecular ion for imiquimod indicated in green is, C5H15NPO4+ 630 
the fragment ion for phosphatidylcholine used to identify the viable epidermis and dermis indicated in blue. C17H32N+ is the 631 
fragment ion for ceramide used to identify the stratum corneum indicated in red. The overlays highlights imiquimod 632 
localisation within the stratum corneum and some near the epidermis just below the stratum corneum. Scale bar: 100 µm 633 
With regards to tape stripping as a method to quantify drug permeation into the superficial layer of 634 
the skin, various groups have observed a reduction in corneocytes removed with tape strip number. 635 
Such reduction in corneocyte extraction is attributed to the increase in corneocyte cohesion with 636 
stratum corneum depth (Chapman et al., 1991; Jacobi et al., 2006; Lademann et al., 2004). In addition, 637 
the increase in skin hydration with skin depth also reduces the ability of the tape adhesive to remove 638 
the corneocyte during the stripping process (Egawa et al., 2006). When analysing the distribution of 639 
imiquimod on the AldaraTM treated skin from Figure 4, it may appear that most imiquimod is with the 640 
top layer of the skin. However, upon closer cross-sectional analysis (Figure 5 a) majority of the 641 
molecule of interest, imiquimod resides within the deeper layer of the stratum corneum. These layers 642 
are not so easily removed by tape stripping and thus are extracted with the remaining skin.  643 
4. Conclusions 644 
In conclusion, the current work highlights the design, fabrication, evaluation and application of drug 645 
loaded polymeric microneedles as a drug delivery platform for the intradermal delivery of imiquimod 646 
for the treatment of nodular BCC. Permeation studies utilising Franz diffusion cells demonstrated that 647 
the imiquimod loaded polymeric microneedles were capable of delivering similar quantities of 648 
imiquimod to the region of tumours, despite a 6-fold lower drug loading, relative to the current clinical 649 
dose of AldaraTM cream used in BCC treatment. This ability of the polymeric microneedle to deliver the 650 
drug to the right target site despite lower drug loading may be of economic benefit while also limiting 651 
the likelihood of side effects. Using a microneedle patch, imiquimod loaded polymeric microneedles 652 
are mechanically inserted and embedded within the dermis upon application which is the target site 653 
for the treatment of nodular BCC. ToF-SIMS analysis of skin cross-sections highlighted the presence of 654 
the embedded drug-polymer matrix within the skin, which retains the drug in the dermis while 655 
reducing the permeation of the drug across the skin. This provides evidence to support the 656 
mechanistic understanding of how the embedded drug-polymer matrix following polymeric 657 
microneedles administration controls the release of drugs. In summary, this work suggests that 658 
imiquimod loaded polymeric microneedles may be of clinical utility for localised intradermal delivery 659 
of imiquimod. Such formulations may provide a less invasive intervention to patients who would prefer 660 
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Figure legends 948 
Figure 1 a) Photograph image of PVPVA microneedles post-fabrication (b) Optical microscopy image 949 
of PVPVA microneedles at 12.5x magnification (c) close up microscopy image - of a single PVPVA 950 
polymeric microneedle at 50x magnification (d) SEM images of PVPVA microneedles at 39x 951 
magnification. 952 
Figure 2 (a) Microscopic images of first Parafilm® treated by PVPVA microneedles (b) Insertion profile 953 
of PVPVA microneedle into Parafilm® layers (c) Microchannels created in ex vivo porcine skin 954 
visualised via the release of methylene blue from PVPVA microneedles (d) Optical microscopy image 955 
of microneedle channels created when the skin is treated with PVPVA microneedles 956 
Figure 3 Amount of drug extracted from skin (tape strips and remaining skin) after 24 hours in the 957 
permeation study. Drug concentration within receptor fluid as a function of time during permeation 958 
study from AldaraTM and imiquimod microneedles. Data are expressed as mean± SEM for n=6. 959 
Differences were calculated using one-way ANOVA, followed by Tukey’s post hoc test, and deemed 960 
significant at p<0.05. n.s = not statistically significant at p>0.05 961 
Figure 4 ToF-SIMS image of skin cross sections from ex vivo porcine skin that were treated with (i) 962 
AldaraTM cream (5% w/w imiquimod) alone (ii) PVPVA microneedles loaded with imiquimod after a 24-963 
hour permeation study. Localisation of semi-dissolved polymeric microneedles within the dermis with 964 
skin treated imiquimod loaded microneedles. C14H17N4+inidicated in green is the molecular ion for 965 
imiquimod, C5H15NPO4+ indicated in blue is the fragment ion for phosphatidylcholine used to identify 966 
the viable epidermis and dermis. C17H32N+ indicated in red is the fragment ion for ceramide used to 967 
identify the stratum corneum. C6H10NO+ indicated in pink is the fragment ion for PVPVA polymer. Scale 968 
bar: 500 µm 969 
 970 
 971 
Figure 5 ToF-SIMS image of skin cross sections from porcine skin that were treated with AldaraTM 972 
cream (5% w/w imiquimod) alone. This analysis was conducted at a higher resolution closer to the 973 
skin surface to image the localisation of imiquimod  near the stratum corneum and epidermis junction. 974 
C14H17N4+ the molecular ion for imiquimod indicated in green is, C5H15NPO4+ the fragment ion for 975 
phosphatidylcholine used to identify the viable epidermis and dermis indicated in blue. C17H32N+ is the 976 
fragment ion for ceramide used to identify the stratum corneum indicated in red. The overlays 977 
highlights imiquimod localisation within the stratum corneum and some near the epidermis just below 978 
the stratum corneum. Scale bar: 100 µm 979 
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